{"id":279504,"date":"2024-10-19T18:52:01","date_gmt":"2024-10-19T18:52:01","guid":{"rendered":"https:\/\/pdfstandards.shop\/product\/uncategorized\/bs-en-iso-10993-112018\/"},"modified":"2024-10-25T15:25:53","modified_gmt":"2024-10-25T15:25:53","slug":"bs-en-iso-10993-112018","status":"publish","type":"product","link":"https:\/\/pdfstandards.shop\/product\/publishers\/bsi\/bs-en-iso-10993-112018\/","title":{"rendered":"BS EN ISO 10993-11:2018"},"content":{"rendered":"
PDF Pages<\/th>\n | PDF Title<\/th>\n<\/tr>\n | ||||||
---|---|---|---|---|---|---|---|
2<\/td>\n | National foreword <\/td>\n<\/tr>\n | ||||||
4<\/td>\n | European foreword <\/td>\n<\/tr>\n | ||||||
7<\/td>\n | Foreword <\/td>\n<\/tr>\n | ||||||
8<\/td>\n | Introduction <\/td>\n<\/tr>\n | ||||||
9<\/td>\n | 1 Scope 2 Normative references 3 Terms and definitions <\/td>\n<\/tr>\n | ||||||
11<\/td>\n | 4 General considerations 4.1 General 4.2 Selection of animal species 4.3 Animal status 4.4 Animal care and husbandry <\/td>\n<\/tr>\n | ||||||
12<\/td>\n | 4.5 Size and number of groups 4.5.1 Size of groups 4.5.2 Number of groups 4.5.3 Treatment controls <\/td>\n<\/tr>\n | ||||||
13<\/td>\n | 4.6 Route of exposure 4.7 Sample preparation 4.8 Dosing 4.8.1 Test sample administration 4.8.2 Dosage volumes <\/td>\n<\/tr>\n | ||||||
14<\/td>\n | 4.8.3 Dosage frequency 4.9 Body weight and food\/water consumption 4.10 Clinical observations 4.11 Clinical pathology <\/td>\n<\/tr>\n | ||||||
15<\/td>\n | 4.12 Anatomic pathology 4.13 Study designs 4.14 Quality of investigation 5 Acute systemic toxicity 5.1 General <\/td>\n<\/tr>\n | ||||||
16<\/td>\n | 5.2 Study design 5.2.1 Preparations 5.2.2 Experimental animals 5.2.3 Test conditions <\/td>\n<\/tr>\n | ||||||
17<\/td>\n | 5.2.4 Body weights 5.2.5 Clinical observations 5.2.6 Pathology <\/td>\n<\/tr>\n | ||||||
18<\/td>\n | 5.3 Evaluation criteria 5.3.1 General 5.3.2 Evaluation of results 5.4 Final report <\/td>\n<\/tr>\n | ||||||
20<\/td>\n | 6 Repeated exposure systemic toxicity (subacute, subchronic and chronic systemic toxicity) 6.1 General 6.2 Study design 6.2.1 Preparations 6.2.2 Experimental animals <\/td>\n<\/tr>\n | ||||||
21<\/td>\n | 6.2.3 Test conditions 6.2.4 Body weights 6.2.5 Clinical observations 6.2.6 Pathology <\/td>\n<\/tr>\n | ||||||
22<\/td>\n | 6.3 Evaluation criteria 6.3.1 General <\/td>\n<\/tr>\n | ||||||
23<\/td>\n | 6.3.2 \u200bEvaluation of results 6.4 Final report <\/td>\n<\/tr>\n | ||||||
24<\/td>\n | Annex A (informative) Routes of administration <\/td>\n<\/tr>\n | ||||||
26<\/td>\n | Annex B (informative) Dosage volumes <\/td>\n<\/tr>\n | ||||||
27<\/td>\n | Annex C (informative) Common clinical signs and observations <\/td>\n<\/tr>\n | ||||||
28<\/td>\n | Annex D (informative) Suggested haematology, clinical chemistry and urinalysis measurements <\/td>\n<\/tr>\n | ||||||
30<\/td>\n | Annex E (informative) Suggested organ list for histopathological evaluation <\/td>\n<\/tr>\n | ||||||
32<\/td>\n | Annex F (informative) Organ list for limited histopathology for medical devices subjected to systemic toxicity testing <\/td>\n<\/tr>\n | ||||||
33<\/td>\n | Annex G (informative) Information on material-mediated pyrogens <\/td>\n<\/tr>\n | ||||||
34<\/td>\n | Annex H (informative) Subchronic rat \u2014 Dual routes of parenteral administration <\/td>\n<\/tr>\n | ||||||
36<\/td>\n | Bibliography <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":" Biological evaluation of medical devices – Tests for systemic toxicity<\/b><\/p>\n |